semaglutide hf Therapy for HFpEF: A step forward brings new hope for people with obesity and diabetes Semaglutide in Patients With Obesity

Vitamin and Nutrition Deficiency

Frequently Asked Questions What are the benefits of Dihexa

Novo Nordisks failure to disclose information that they possessed regarding the causal association between the use of GLP-1RAs and the risk of developing necrotizing pancreatitis, rendered the warnings for Ozempic inadequate. Necrotizing pancreatitis occurs when part of the pancreas dies due to inflammation or injury

An initial 4-month dose escalation period evaluated different doses (120, 240, and 360 g) and administration frequencies (two or three times daily) for pramlintide and was followed by an 8-month extension of the pre-assigned pramlintide treatment regime

Current UK clinical guidance does not support berberine as a substitute for evidence-based diabetes treatments

For more information please view the Barchart Disclosure Policy here.